Novel therapies in melanoma (Q37957141)

25 August 2017

title

Novel therapies in melanoma (English)

1 reference

25 August 2017

Benjamin Scheier

1

1 reference

25 August 2017

Rodabe Amaria

series ordinal

2

1 reference

25 August 2017

Karl Lewis

series ordinal

3

1 reference

25 August 2017

Rene Gonzalez

series ordinal

4

1 reference

25 August 2017

publication date

1 December 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

3

1 reference

25 August 2017

issue

12

1 reference

25 August 2017

page(s)

1461-1469

1 reference

25 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Patterns of somatic mutation in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

High frequency of BRAF mutations in nevi

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Ordered phosphorylation of p42mapk by MAP kinase kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Phosphoinositide 3-kinase in disease: timing, location, and scaffolding

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.136

21 January 2018

Identifiers

DOI

10.2217/IMT.11.136

1 reference

25 August 2017

1 reference